← Back to screener

GILEAD SCIENCES, INC. GILD

Rank #1212 · Nasdaq · $211.9B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
51.8
P/E
37.4
P/B
10.96
ROE
29.3%
Op. Margin
28.0%
Debt Ratio
205%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E 37.4x, P/B 10.96x. Ranks in the top 64% of the universe.

Profitability ★★★★☆
Excellent

ROE 29.3%. Ranks in the top 12% of the universe.

Safety ★★☆☆☆
Weak

Debt ratio 205%. Ranks in the top 63% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★☆☆☆
Weak

Revenue decline of 0.6% year over year. Ranks in the top 66% of the universe.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$7.0B$3.5B$2.6B$5.9B50.398
2012$7.9B$4.0B$2.9B$6.7B49.8157
2013–$3.8B$2.8B$9.3B–128
2014–$4.0B$2.6B$11.4B–99
2015–$4.5B$3.1B$15.4B–125
2016–$15.3B$12.1B$18.5B–179
2017–$22.2B$18.1B$18.9B–202
2018$30.4B$17.6B$13.5B$20.4B58.0244
2019$26.1B$14.1B$4.6B$21.4B54.1198
2020$22.1B$8.2B$5.5B$22.5B37.1174
2021$22.4B$4.3B$5.4B$18.2B19.1276
2022$24.7B$4.1B$0.1B$21.1B16.5223
2023$27.3B$9.9B$6.2B$21.2B36.3197
2024$27.3B$7.3B$4.6B$22.8B26.9172
2025$27.1B$7.6B$5.7B$19.3B28.0205

← See the full screener